COVID-19

The use of B-cell depleting therapies does not increase the risk of an infection with COVID-19 among people with multiple sclerosis (MS) who have been vaccinated, according to the findings of a new study by U.S. researchers. While such treatments did compromise the body’s ability to develop antibodies against…

Hospitalization for severe COVID-19 is significantly associated with a twofold higher risk of developing multiple sclerosis (MS), according to a study involving nearly the entire population of Sweden. No increased risk of MS was found among those who tested positive for SARS-CoV-2, the virus that causes COVID-19, or received…

Well, it’s that time of the year again: flu season. I guess you could say it’s COVID-19 season, too, though confirmed and probable cases of COVID-19 started increasing in late June here in Kansas City, Missouri, and continued to rise at least through August. Detection of COVID-19 through wastewater…

People with multiple sclerosis (MS) in England had a seven times greater risk of hospitalization and a fourfold increased risk of death from COVID-19 in 2022 than did the general population, according to a study of almost 12 million people in the European nation. The elevated risk of both…

Two types of chemicals in household disinfectants and furniture can disrupt the development of oligodendrocytes, the brain cells chiefly responsible for making myelin, a new study shows. The finding suggests that exposure to these chemicals may be a risk factor for disorders related to myelin such as…

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at some of what’s been happening. MS relapses and COVID-19 Since COVID-19 became a concern over three years ago, I’ve read many comments…

COVID-19 doesn’t appear to increase the likelihood of a relapse, where new symptoms suddenly appear or existing ones worsen, for people with multiple sclerosis (MS), according to a meta-analysis of more than a dozen studies. The findings alleviate some of the concerns MS patients may have about developing COVID-19,…

The overall financial impact of changes in treatment and delayed diagnoses for people with multiple sclerosis (MS) in Canada due to the COVID-19 pandemic likely will be in the hundreds of millions of dollars between 2020 and 2024 in terms of extra healthcare costs and lost productivity, as well…

My wife and I got the latest COVID-19 vaccine the other day, the first of three vaccines we’ll be getting this fall. The others are the seasonal flu vaccine and the respiratory syncytial virus (RSV) vaccine. This was my sixth COVID-19 vaccine, and I’ve received a…

Certain COVID-19 vaccines do not appear to worsen the symptoms of multiple sclerosis (MS), and may provide protection for at least six months after a booster dose, according to a study in Spain. The study specifically examined mRNA vaccines, or those that use a piece of RNA to teach…

People with multiple sclerosis (MS) who receive vaccines against influenza — commonly known as flu shots — as well as diphtheria, polio, pneumoccocus, and multiple other pathogens are not significantly more likely to be hospitalized due to a disease relapse, according to a new study in France. Similar…

It’s been almost two and a half years since my first COVID-19 vaccine — eight months since my most recent booster — and my COVID-19 antibodies seem to still be doing their thing. I know this because, after having nine test tubes of blood drawn, the lab results…

Since the early days of the COVID-19 vaccination program, disinformation claiming that the vaccines can induce multiple sclerosis (MS) has swirled around social media. Recently, there’s been a resurgence of this type of post, sparked by a report published on the World Health Organization (WHO) website titled “…

Anne Rosales is a mother of three grown children, grandmother, and community volunteer. She was diagnosed with multiple sclerosis (MS) in her mid-50s. She holds a Master of Business Administration from Stanford University and is a certified aging-in-place specialist. Rosales blogs about midlife health and wellness at…

Those with multiple sclerosis (MS) may want to roll up their sleeves again for a COVID-19 vaccine. I’m thinking about whether to join them. About 10 days ago, an advisory committee of the U.S. Centers for Disease Control and Prevention (CDC) supported a recommendation that people 65…

COVID-19 had finally left me. Its only trace was a pair of slimy hands. For a month, I requested a towel in bed to wipe them dry. My wife, Jane, told me my hands were fine; my phone’s screen, however, didn’t agree. As my companion in the hospital…

Note: This column was updated March 30, 2023, to remove the statement that Briumvi is more potent than Ocrevus or Kesimpta as there have been no trials comparing the three therapies’ potency. Welcome to “MS News Notes,” a Monday morning column in which I comment on multiple sclerosis (MS)…

Infection with the virus that causes COVID-19 significantly accelerates neurological disability in people with multiple sclerosis (MS), at least in the first months after infection, a study from Belgium reported. A more severe case of COVID-19, one requiring hospitalization, also significantly associated with a faster worsening of MS…

If you noticed my sudden disappearance, it wasn’t because I was sacked. Surprising, I know. Just “MS MIA” — missing in action with multiple sclerosis. While raving in the hospital, I was suddenly moved to my own private room. In Britain’s National Health Service (NHS), this could only mean…

Because people with multiple sclerosis (MS) usually undergo regular MRI scans to image their brains, their data could help researchers learn more the long-term effects of COVID-19 on brain tissue. That’s the argument by a team of researchers in the paper, “Multiple sclerosis as a…

People with multiple sclerosis (MS) being treated with Ocrevus (ocrelizumab) less frequently than the recommended every six months are not more likely to experience inflammatory disease activity, an analysis of some 360 patients whose dosing schedules changed during the COVID-19 pandemic suggests. Nicole Bou Rjeily, MD, a postdoctoral…

It was bound to happen. Even though it’s been more than three years since COVID-19 reared it head in Wuhan, China, and even though I’ve had five of the COVID-19 vaccine shots recommended by the U.S. Centers for Disease Control and Prevention — two primary series doses and three…

Welcome to “MS News Notes,” where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Could COVID-19 trigger MS? Since the start of the COVID-19 pandemic, there have been scattered reports of people who’ve developed neurological disorders,…

A protein in the virus that causes COVID-19 is structurally similar to several proteins targeted by the immune system in multiple sclerosis (MS), a new study shows. The results provide a potential mechanism for how COVID-19 could trigger MS-like disease in susceptible individuals, researchers said. The study, “…

Tevogen Bio has announced plans to develop T-cell therapies targeting the Epstein-Barr virus (EBV), a herpes virus known to be a major environmental risk factor for multiple sclerosis (MS). The decision comes on the heels of positive safety data from a proof-of-concept Phase 1 Tevogen trial that…

It’s the time of the season. Every year around this time, I get a seasonal flu shot. I’ve been doing this for as long as I can remember, certainly all of my adult life. But this year is a little different. There are now three flu vaccines preferentially recommended…

Ah, after living the majority of the last three years of my life indoors, I do tend to spark conversation with my carers. But if I keep quiet, they’re more than happy to do so, too, as they repetitively deal with the rigmarole of getting me ready every morning. It’s…

The Accelerated Cure Project (ACP) for multiple sclerosis (MS) is teaming up with Quest Diagnostics to study how MS patients respond to COVID-19 vaccines. “Understanding the immune response to the COVID-19 vaccine doses in a longer-term study in people with MS will provide tremendous insights into not…